Synovo

Our team

Built by clinicians, engineers and rheumatology experts

Synovo is led by its two founders, advised by leading rheumatology academics at the University of Leeds, and used every day by clinicians at our sites in the UK and abroad.

Every feature is shaped with the doctors who care for people living with arthritis, so what you record at home is something your care team can trust.

Dr Nasir Khan and Nick Hughes, Synovo's founders, at the World Health Expo
Our founders at the World Health Expo

94%correlation with DAS28, the clinic's own measure

97%Directional agreement when DAS28 changed by 0.6 points or more

3active clinical sites, in the UK, Pakistan and Bahrain

UKCAmarked medical device, registered with the MHRA

Founding team

The founders

One founder leads the product and technology, the other the clinical and commercial route to patients around the world.

Nick Hughes

Nick Hughes

Founder

  • Product and technical architecture
  • Regulated clinical software and digital health development
  • NHS pathway understanding
  • Previously at Touch Surgery
United KingdomLinkedIn
Dr Nasir Khan

Dr Nasir Khan

Co-founder

  • Doctor of Medicine
  • Sloan Fellow in Strategy and Leadership, London Business School
  • Commercial strategy, scaling and healthcare commercialisation
  • UK, GCC and international market development
United Kingdom and GCCLinkedIn

Medical advisors

Guided by leading rheumatology research

Rheumatology academics at the University of Leeds advise on study design, clinical evidence and how Synovo fits into patient care.

Professor Dennis McGonagle

Professor Dennis McGonagle, PhD, FRCPI

Medical Advisor, University of Leeds

  • Professor of Investigative Rheumatology
  • Head of Experimental Rheumatology
  • Director of International Strategy, Leeds Institute of Rheumatic and Musculoskeletal Medicine
Chapel Allerton Hospital, Leeds
Professor Francesco Del Galdo

Professor Francesco Del Galdo, MD, PhD

Medical Advisor, University of Leeds

  • Susan Cheney Professor of Experimental Medicine
  • Lead, Raynaud's and Scleroderma Programme
  • Consultant Rheumatologist, Leeds Teaching Hospitals
  • President, European Scleroderma Trial and Research Consortium (EUSTAR)
University of Leeds and NIHR Biomedical Research Centre

Clinical site leads

In use with patients today

Clinicians at our active sites lead the day to day clinical work, from the NHS clinical audit to our international studies.

  • Luton and Dunstable, NHS
  • Pakistan
  • Bahrain
Dr Muhammad Nisar

Dr Muhammad Nisar

Clinical Lead, Bedfordshire

  • Consultant Rheumatologist
  • Director of Research and Development
  • Lead clinician, NHS clinical audit at Luton and Dunstable
Dr Shehla Javed Akram

Dr Shehla Javed Akram

Clinical Lead, Pakistan

  • Clinical Nutritionist
  • Vice President, Federation of Pakistan Chambers of Commerce and Industry
  • Leads patient enrolment and on site governance
Dr Fatema Hajji

Dr Fatema Hajji

Clinical Lead, Bahrain

  • Rheumatology
  • RCSI collaboration

Strategic advisors

Experience in adoption, funding and growth

A small group advising on NHS adoption, investment and how we tell the Synovo story.

Catherine Gabela

Catherine Gabela

Strategic Advisor

  • NHS adoption, governance and pathway strategy
Cyrus Hiramanek

Cyrus Hiramanek

Strategic Advisor

  • Fundraising, investor positioning and US market strategy
Mark Bishop

Mark Bishop

Strategic Advisor

  • Marketing, brand and commercial positioning

For patients

In safe hands

Synovo is a UKCA marked medical device, developed with rheumatologists and checked against the measures used in clinic.

  • Your data is encrypted and held on secure servers
  • Built to UK GDPR from the start
  • Your results are shared only with your care team

For investors

A validated platform, ready to scale

Clinical validation against DAS28, live NHS and international sites, and a team that spans medicine, regulated software and commercial growth.

The evidence

Why regular monitoring matters

Measuring arthritis often, and acting on the results, leads to better outcomes. Research also shows it can be done safely at home, with fewer trips to hospital.

  • 65% vs 16%

    Close monitoring leads to remission

    People whose arthritis was measured regularly and treated to a target reached remission far more often than those given routine care.

    Grigor et al., The Lancet, 2004. The TICORA study, a randomised controlled trial.Read the study (opens in a new tab)
  • Monthly

    Recommended by NICE

    NICE advises measuring disease activity, using a score such as DAS28, every month until remission or low disease activity is reached.

    NICE guideline NG100, 2018 (updated 2020). Rheumatoid arthritis in adults: management.Read the guideline (opens in a new tab)
  • 58% fewer

    Remote follow up works

    Following patients up remotely controlled their arthritis as well as clinic visits did, with far fewer face to face appointments.

    de Thurah et al., Arthritis Care and Research, 2018. A randomised controlled trial of 294 patients.Read the study (opens in a new tab)
  • 20 million+

    A growing need

    Over 20 million people, around a third of the UK, live with a musculoskeletal condition such as arthritis, putting real pressure on clinics.

    Versus Arthritis (now Arthritis UK), 2023. The State of Musculoskeletal Health.Read the report (opens in a new tab)